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Abstract:
Background:
Intraoperative Floppy Iris Syndrome (IFIS) is an important cause of surgical complications and iris defects in patients undergoing
phacoemulsification  that  were  treated  with  selective  subtype  α1A  receptor  antagonists  for  a  long  period  of  time.  To  date,  no
definitive preventive strategy has emerged, yet. The need of prophylaxis is dictated by the high prevalence of males affected by
benign prostatic hyperplasia undergoing cataract surgery.
Objective:
To identify the best prophylactic strategy in groups at risk of IFIS development by comparing two mydriatic treatments in course of
phacoemulsification surgery.
Methods:
81 eyes of 81 patients in treatment with Tamsulosin were enrolled in the study. 43 eyes were treated with atropine sulfate 1% while
38 eyes received an injection of mydriatic solution containing epinephrine in the anterior chamber. All phacoemulsifications were
videotaped in order to assess the occurrence of IFIS and the severity of the syndrome.
Results:
The treatment group showed a statistically significant reduction (p = 0.0115) of floppy iris syndrome incidence, from 86.05% (37/43)
of the atropine group to 60.53% (23/38). The analysis showed a reduction of IFIS mild form only, whereas the incidence of severe
forms remained unchanged.
Conclusions:
We believe  that  IFIS  may arise  through two different  mechanisms:  pharmacological  antagonism and  anatomical  modifications.
Patients suffering from mild forms of the disease showed a statistically significant reduction of IFIS incidence after intraoperative
prophylaxis due to epinephrine’s ability to displace Tamsulosin, resulting in the increase of iris tone when the disease is caused
mainly by receptorial antagonism. On the contrary, prophylaxis does not deliver any valuable result in case of severe forms where the
anatomical variations play a major role.
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1. INTRODUCTION
The use of  selective subtype α1A Receptor Antagonists  (ARA α1A) (such as tamsulosin and silodosin)  to treat
Benign Prostatic Hyperplasia (BPH) has shown to reduce the hypotensive side effects of previous drugs (alfuzosin,
doxazosin), increasing, however, the occurrence of ocular side effects [1].
Induced alterations become more evident during phacoemulsification procedures, leading to Intraoperative Floppy
Iris Syndrome (IFIS). First described in 2005 by Chang and Campbell [2], IFIS is characterized by the presence of the
classical triad consisting in fluctuation, miosis and progressive iris stroma prolapse through the surgical corneal tunnel,
despite microincisions of 2.75, 2.2 or 1.8 mm. The clinical presentation may vary from mild to severe forms in which
all three features occur [2].
The  presence  of  IFIS  often  increases  the  risk  of  posterior  capsule  lens  rupture  with  vitreous  loss,  lens  nucleus
displacement into the vitreous chamber, iris lacerations or atrophy and loss of ocular pigment, hyphema, and zonular
disinsertion [2, 3].
The incidence of IFIS is about 0.5-2% in people who have never taken alphalitic drugs compared with 70% in those
treated with alpha antagonists [4].
Extensive efforts have been made to identify the best preventive strategy [4]. To date, no definitive protocol (which
has to be not only universally acknowledged but also standardized) has emerged, yet. The need of a preventive strategy
is dictated by the high prevalence of males affected by benign prostatic hyperplasia undergoing cataract surgery. This
problem  is  becoming  more  relevant  also  due  to  life  expectancy  elongation.  Moreover,  female  subjects  are  not
completely  spared  by  this  syndrome,  since  numerous  other  drugs  including  zuclopenthixol,  risperidone,  mianserin,
chlorpromazine,  quetiapine,  labetalol  and  saw  palmetto  extract  [5  -  7]  were  associated  with  IFIS,  although  less
frequently. The main aim of this work is the comparison of the prophylactic efficacy of two mydriatic treatments, one
that  acts  as  a  parasympatholytic  (thus  pupiloplegic)  and  the  other  based  on  the  administration  of  an  intracameral
adrenergic agent.
2. MATERIAL AND METHODS
This study adheres to the principles of the Declaration of Helsinki and received the approval of the institutional
ethics committee of the center where it was conducted.
Eighty-one eyes (from 81 male patients) under treatment with uninterrupted Tamsulosin (for at least 1 year) and
affected  by  cataracts  were  enrolled  in  the  study  and  enlisted  for  phacoemulsification  surgery.  Participants  were
subjected to preoperative ophthalmological evaluation including collection of personal data, ocular examination at the
slit  lamp,  fundus  examination  after  pharmacological  mydriasis,  acquisition  of  keratometric  values  with  Javal
ophthalmometry,  acquisition  of  corneal  topography  data  with  Oculus  Pentacam (with  collection  of  central  corneal
thickness  values,  anterior  chamber  depth  and  iridocorneal  angle  width),  intraocular  pressure  measurement  with
Goldman applanation tonometry, execution of ocular biometry with ultrasound and optical methods, manifest refraction
measurement, uncorrected and best-corrected visual acuity examination.
43 patients were treated with treatment pattern A and 38 patients with the pattern B. Patients with pseudoexfoliation
syndrome, miotic diabetic pupil, chronic use of miotic drugs, were excluded from the study as well as those with a
history of α1 adrenergic receptor antagonist intake other than tamsulosin.
All patients received an ocular mydriatic insert (tropicamide/phenylephrine 0.28/5.4 mg) placed in the conjunctival
sac 1 hour before surgery. In addition, Group A received atropine sulfate 1% instillation at 40 and 20 minutes before
surgery, while Group B received an injection of a mydriatic solution in the Anterior Chamber (AC) at the beginning of
surgery.
Group B’s  solution,  similar  to  the epi-shugarcaine formulated by Shugar  [8],  featured 2% lidocaine,  adrenaline
1mg/ml  without  bisulfites  and  ophthalmic  balanced  salt  solution  (BSS  Plus)  at  the  following  concentrations:
epinephrine 1:3000 in a solution composed of lidocaine 2:5 and BSS Plus. Sulfite-free epinephrine was used to avoid
the risk of endothelial damage as reported in Liou’s studies [9].
The BSS Plus was preferred to normal BSS because the pH of the solution, at the above-mentioned concentrations,
did not meet the safety criteria set out by Gonnering (the mean pH out of 6 preparations was 6.05, related to regular
BSS, and 7.04, if related to BSS plus) [10].
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The solution was prepared in the operating room 10 minutes before use and the surgeon injected from 0.5 to 0.6 cc
in front of the iris after performing the corneal incision. After 15-20 seconds an ophthalmic viscosurgical device (OVD)
was injected (in our study 4% chondroitin sulfate, 3% hyaluronate) and surgery proceeded with regular procedure.
All  81  phacoemulsifications  were  performed  by  the  same  surgeon  using  the  same  technique  and  equipment
(phacoemulsificator Bausch & Lomb STELLARIS), and videotaped to assess the occurrence of IFIS and the severity of
the  syndrome  in  accordance  with  Chang  and  Campbell  criteria  [11]  referring  as  absent  (stable  normal  iris),  mild
(noticeable iris billowing without significant miosis or iris prolapse) moderate (iris billowing accompanied by either iris
prolapse or pupil diameter reduction ≥2 mm) or severe form (iris billowing accompanied by iris prolapse with pupil
diameter reduction ≥2 mm). A blinded reviewer performed IFIS grading for each video.
Blood pressure and heart rate were measured five minutes before surgery and 5 minutes after the beginning of the
procedure.
Six months after surgery Best Corrected Visual Acuity (BCVA) was measured and any adverse event recorded.
Potential biases such as age, diabetes, glaucoma, high blood pressure, cataract entity, ocular axial length, iridocorneal
angle, AC depth and iris color were checked.
In data analysis, the significance of differences between proportions was tested using the Chi square test or Fisher
Exact Test if needed, while the significance of differences for other quantitative data was tested using Student’s t-test if
the distribution was normal and Mann–Whitney–Wilcoxon test in case of non-parametric values.
3. RESULTS
No statistically  significant  differences  in  the  distribution of  variables  (age,  nuclear  density,  ocular  axial  length,
iridocorneal angle, anterior chamber depth, diabetes, hypertension, macular degeneration, glaucoma, iris color) were
observed between groups under study Tables 1 and 2.
Table 1. Quantitative participants’ data.
Variable
Mean ± SD
p-value (95% CI)
A Group B Group
Age (y) 74,8 ± 6,7 73,4 ± 6 0.328 (-1.43 – 4.23)
Nuclear density1 13 ± 3 11,8 ± 2 0.040 (0.06 – 2.34)
Ocular Axial lenght2 (mm) 22,9(4) ± 0,5 22,9(5) ± 0,6 1.000 (-0.24 – 0.24)
Iridocorneal angle3 (°) 37 ± 10 31,3 ± 7,6 0.005 (1.73 – 9.67)
A.C6. depth2 (mm) 2,8 ± 0,6 2,6 ± 0,3 0.067 (-0.01 – 0.41)
1 measured with “Pentacam Nucleus Staging” (Oculus Petacam).
2 measured with Optical biometry (ZEISS IOL MASTER)
3 measured with Pentacam HR -Oculus-.
4 three patients data lost
5 four patients data lost
6 A.C. anterior chamber
Table 2. Qualitative participants’ data.
Variable
A Group
n/total (%)
B Group
n/total (%)
p-value
Diabetes 13/43 (30.23%) 11/38 (28.95%) 1.000
Hypertension 35/43 (81.39%) 28/38 (73.68%) 0.435
Maculopathy 9/43 (20.93%) 9/38 (23.68%) 0.795
Glaucoma 2/43 (4.65%) 1/38 (2.63%) 1.000
Iris Color
light
dark
11/43 (25.58%)
32/43 (74.41%)
9/38 (23.68%)
29/38 (76.32%)
1.000
1.000
Lenght of tamsulosin intake at recruitment time
1-3 years 15/43 (34.88%) 15/38 (39.47%) 0.818
3-5 years 6/43 (13.95%) 4/38 (10.53%) 0.743
>5 years 22/43 (51.16%) 18/38 (47.37%) 0.825
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There was a total of 60 IFIS events (74%) in patients taking tamsulosin. Group B showed a statistically significant
difference (p = 0.0115) of floppy iris syndrome incidence - 60.53% (23/38 patients) - when compared with Group A -
86.05% (37/43 patients). Table 3 compares treatment group with syndrome severity.
Table 3. IFIS severity related to prophylactic treatment.
IFIS
A Group
n/N (%)
B Group
n/N (%)
p-value
None 6/43 (13.95%) 15/38 (39.47%) 0.0115
Mild 15/43 (34.8%) 6/38 (15.79%) 0.0748
Moderate 2/43 (4.65%) 1/38 (2.63%) 1.0000
Severe 20/43 (46.51%) 16/38 (42.11%) 0.8232
Overall IFIS cases 37/43 (86.05%) 23/38 (60.53%) 0.0115
Systolic Blood Pressure (SBP) and Heart Rate (HR) showed no significant differences in the study groups indicating
the systemic safety of intracameral epinephrine at doses 1:3000.
Postoperative  complications  occurred  in  33%  (12  out  of  36  subjects)  of  severe  IFIS  cases  (44%  of  overall
participants),  whereas  none  of  the  subjects  who  developed  mild  or  moderate  IFIS  suffered  from  postoperative
complications.  The  main  observed  complication  was  iris  subatrophy  due  to  iris  trauma  following  prolapse  and
repositioning maneuvers (8 cases in group A and 3 in group B, p = 0.28), while one subject from group B suffered from
postoperative iris defect (p = 0.44).
All patients achieved a BCVA of 20/25 minimum, regardless of the mydriatic treatment used and IFIS severity.
4. DISCUSSION
Phacoemulsification is one of the most performed surgical operations and the number of males with benign prostatic
hyperplasia  needing  cataract  surgery  is  increasing  due  to  life  expectancy  elongation.  Tamsulosin  is  the  most  used
receptor antagonist due to its α1A receptor selectivity but it is also the most common cause of IFIS, hence the interest in
developing preventive measures.
This study was designed to evaluate the efficacy of two prophylactic treatments for IFIS in people treated with
tamsulosin, focusing on the application of a drug stimulating the activity of iris dilator muscle in comparison with a
pharmacologic block of iris constrictor muscle.  In our study, 1% atropine was used as the parasympatholytic agent
while the mydriatic solution conceived for this study – in accordance to findings from the existing literature made by
prominent supporters such as Schulze, Masket and Belani [12, 13] - has been adopted as the sympathomimetic agent.
The interesting finding of a statistically significant IFIS reduction (p = 0.0115), in Group B, especially for mild
forms,  when  treated  with  intracameral  epinephrine  1:3000  becomes  even  more  remarkable  in  the  light  of  another
consideration. In fact, this assessment is very encouraging for the development of a relatively unexplored and novel
prophylaxis regimen in association with “rational” alpha-antagonist drug discontinuation. Given recent autoptic and in
vivo evidence of iris dilator muscle thickness reduction, associated with denervation and fiber vacuolization in patients
taking Tamsulosin [14, 15], we believe that IFIS may arise through two different mechanisms. In the early stages of
treatment  with  selective  ARAα1A,  the  cause  of  floppy  iris  would  be  related  to  the  pharmacological  receptor
antagonism,  whereas,  after  continuous  medication  use,  the  anatomical  modifications  become  the  predominant
mechanism  leading  to  incomplete  resolution  after  treatment  interruptions.
The significant reduction of IFIS mild forms can be explained by the epinephrine’s ability to displace Tamsulosin,
leading to an increase of the iris tone, whereas the inefficacy of the mydriatic solution under evaluation in case of severe
stages would be attributable to anatomical variations. The direct adrenaline activity on alpha1 receptor has therefore,
greater effects in comparison with the indirect action of atropine. Therefore, the lower efficacy of atropine observed in
this study may be due to its inability to displace Tamsulosin from the α1A receptor, since its mechanism of action is
based on the inhibition of iris constrictor muscle activity.
Limits of the study are related to the relatively small sample size and lack of long-term prospective data, such as
reports on postoperative complications at one year, in order to evaluate whether IFIS remains primarily a problem for
ophthalmologists,  who  must  deal  with  it  in  course  of  phacoemulsification  surgery,  and  investigate  eventual
repercussions  on  the  quality  of  patients’  vision.
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Further evaluations would be useful  to comprehend the timing of  ARAα1A intake that  leads to iris  irreversible
alterations  in  order  to  establish  both  prophylactic  measures  of  tamsulosin  suspension  and/or  preoperative  use  of
adrenergic agents, limiting techniques of mechanical dilation (such as iris hooks) when irreversible anatomical damage
has occurred.
Patients  should  be  addressed  to  ophthalmological  evaluation  before  IPB  treatment  prescription,  especially  in
patients complaining a decreased bilateral vision due to cataracts.
In the light of an interdisciplinary protocol, attention should be focused also to common alpha-1 antagonist drugs
prescribed by cardiologists and psychiatrists, since antagonist activity on the α1 receptor may be the main cause of IFIS
also in women.
We believe that more attention should be given to prevention, rather than prophylaxis, through the establishment of
an interdisciplinary collaboration with urologists and general practitioners. The former would treat benign prostatic
hypertrophy with non-selective ARA α1 drugs (when possible), since it is reported by numerous studies, such as the one
by Chang and Campbell [11], to cause lesser IFIS occurrence. This would leave Tamsulosin to be prescribed after the
conclusion of the ophthalmological surgical process (cataract extraction in both eyes) and general practitioners should
act upon both urologists’ and ophthalmologists’ supervision.
CONCLUSION
This study confirms the ocular and systemic safety of sulphite free epinephrine 1:3000 buffered in BSS Plus and
how IFIS does not impact on visual results if handled by experienced surgeons (since all patients achieved a BCVA
minimum of 20/25). The mydriatic intracameral solution containing epinephrine was more effective than atropine in
preventing IFIS in its mild form, but not in severe forms in which anatomical changes have occurred. According to data
obtained,  the use of  intraoperative adrenergic agents  would be ineffective in IFIS progression “containment” when
anatomical alterations are suspected.
Given these considerations, the widespread opinion on the futility of ARAα1A withdrawal may be reconsidered,
leading to a rational interruption in a subset of patients.
ABBREVIATION LIST
ARA α1A = α1A Receptor Antagonists
BPH = Benign Prostatic Hyperplasia
IFIS = Intraoperative Floppy Iris Syndrome
AC = Anterior Chamber
BSS = Balanced Salt Solution
OVD = Ophthalmic Viscosurgical Device
BCVA = Best-Corrected Visual Acuity
SBP = Systolic Blood Pressure
HR = Heart Rate
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